Q3 2025 Xeris Biopharma Holdings Inc Earnings Call Transcript
Key Points
- Xeris Biopharma Holdings Inc (XERS) reported a record-setting quarter with total product revenue exceeding $74 million, marking a 40% increase year over year.
- The company raised the lower end of its full-year total revenue guidance, now expecting total revenue to be between $285 million and $290 million, a 42% increase at the midpoint.
- Rekorlev was a primary growth engine, with revenue more than doubling compared to the prior year, driven by a 108% increase in the average number of patients on therapy.
- Xeris Biopharma Holdings Inc (XERS) achieved significant positive cash flow and net income for the first time in the company's history, highlighting its growing commercial strength.
- The company reported a strong adjusted EBITDA growth, demonstrating the scalability of its business and reinforcing its ability to translate consistent top-line performance into bottom-line results.
- The company anticipates an increase in both SG&A and R&D expenses starting in the fourth quarter, which may impact quarterly EPS results.
- There is expected variability in quarterly EPS results due to ongoing investments in the commercial organization and preparation for the phase three clinical study of XP 8,121.
- The expansion of the sales force and patient support teams will require time for new representatives to reach optimal productivity, potentially delaying immediate returns on investment.
- Xeris Biopharma Holdings Inc (XERS) faces competitive dynamics, particularly with potential new entrants in the market, which could impact its market share.
- The company is making multi-year investments in infrastructure, which may strain resources and require careful management to ensure alignment with strategic priorities.
Hello everyone, and thank you for joining us today for the Xeris Biopharma Q3 2025 earnings conference call. (Operator Instruction). I'd now like to hand over to your host, Allison Wey, Senior Vice President of Investor Relations and Corporate Communications to begin. Allison.
Thank you, (Inaudible). Good morning and welcome everyone to the Xeris Biopharma Third quarter 2025 earnings call. You can find this morning's earnings release on our and our detailed financial results on the investor relations section of our website. Today, I'm joined by John Shannon, CEO, and Steve Pieper, our CFO. After our prepared remarks, we'll open a line for questions.
Before we begin, I'd like to remind you that this call will contain certain forward-looking statements concerning the company's future expectations, plans, projects, and financial performance. Forward-looking statements are subject to risks and uncertainty that could cause actual results to differ materially from those
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
